Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy: problems and practices.
Clin Neuropharmacol. 1986; 9 Suppl 1:S23-36.CN

Abstract

Treatment of Parkinson's disease is not difficult in the early stages of the disease; a therapeutic regimen of carbidopa-levodopa or possibly, a combination of carbidopa-levodopa and bromocriptine, provides the best therapeutic results. There is no reason to withhold carbidopa-levodopa therapy early in the disease. During the more advanced stages of the disease, in addition to meticulous titration of carbidopa-levodopa, the administration of a dopamine agonist (such as bromocriptine), amantadine, or an anticholinergic agent may be required in an attempt to smooth the therapeutic effect. All of these drugs, with the exception of amantadine, require small initial doses with subsequent cautious increases in dosage. Mental side effects are less likely to occur with carbidopa-levodopa therapy than with any of the other drugs.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

3708606

Citation

Muenter, M D.. "Pharmacotherapy: Problems and Practices." Clinical Neuropharmacology, vol. 9 Suppl 1, 1986, pp. S23-36.
Muenter MD. Pharmacotherapy: problems and practices. Clin Neuropharmacol. 1986;9 Suppl 1:S23-36.
Muenter, M. D. (1986). Pharmacotherapy: problems and practices. Clinical Neuropharmacology, 9 Suppl 1, S23-36.
Muenter MD. Pharmacotherapy: Problems and Practices. Clin Neuropharmacol. 1986;9 Suppl 1:S23-36. PubMed PMID: 3708606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy: problems and practices. A1 - Muenter,M D, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - S23 EP - 36 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 9 Suppl 1 N2 - Treatment of Parkinson's disease is not difficult in the early stages of the disease; a therapeutic regimen of carbidopa-levodopa or possibly, a combination of carbidopa-levodopa and bromocriptine, provides the best therapeutic results. There is no reason to withhold carbidopa-levodopa therapy early in the disease. During the more advanced stages of the disease, in addition to meticulous titration of carbidopa-levodopa, the administration of a dopamine agonist (such as bromocriptine), amantadine, or an anticholinergic agent may be required in an attempt to smooth the therapeutic effect. All of these drugs, with the exception of amantadine, require small initial doses with subsequent cautious increases in dosage. Mental side effects are less likely to occur with carbidopa-levodopa therapy than with any of the other drugs. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/3708606/Pharmacotherapy:_problems_and_practices_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=3708606.ui DB - PRIME DP - Unbound Medicine ER -